FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

NCT05913037 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

167

Enrollment

INDUSTRY

Sponsor class

Conditions

Neurofibromatosis 1
Plexiform Neurofibroma
NF1

Interventions

DRUG: Test group (Group A): FCN-159 8 mg, orally, once daily;
DRUG: Control group (Group B): Placebo, orally, once daily;

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.